JP2018517419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517419A5 JP2018517419A5 JP2017565248A JP2017565248A JP2018517419A5 JP 2018517419 A5 JP2018517419 A5 JP 2018517419A5 JP 2017565248 A JP2017565248 A JP 2017565248A JP 2017565248 A JP2017565248 A JP 2017565248A JP 2018517419 A5 JP2018517419 A5 JP 2018517419A5
- Authority
- JP
- Japan
- Prior art keywords
- attenuated strain
- salmonella enterica
- seq
- salmonella
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002238 attenuated effect Effects 0.000 claims 30
- 241001138501 Salmonella enterica Species 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 9
- 102000053602 DNA Human genes 0.000 claims 8
- 241000607142 Salmonella Species 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 108091008048 CMVpp65 Proteins 0.000 claims 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 4
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 238000011275 oncology therapy Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims 2
- 101710127857 Wilms tumor protein Proteins 0.000 claims 2
- 102000025171 antigen binding proteins Human genes 0.000 claims 2
- 108091000831 antigen binding proteins Proteins 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001803.4 | 2015-06-18 | ||
| EP15001803 | 2015-06-18 | ||
| PCT/EP2016/001004 WO2016202459A1 (en) | 2015-06-18 | 2016-06-16 | Vegfr-2 targeting dna vaccine for combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517419A JP2018517419A (ja) | 2018-07-05 |
| JP2018517419A5 true JP2018517419A5 (cg-RX-API-DMAC7.html) | 2019-05-30 |
| JP6947649B2 JP6947649B2 (ja) | 2021-10-13 |
Family
ID=53476620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565248A Active JP6947649B2 (ja) | 2015-06-18 | 2016-06-16 | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン |
Country Status (19)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019112977A (ru) * | 2016-11-04 | 2020-12-04 | Факсимм Аг | Днк-вакцина, нацеленная на wt1, для комбинированной терапии |
| SG11201907391SA (en) * | 2017-02-17 | 2019-09-27 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| US11357842B2 (en) | 2017-03-17 | 2022-06-14 | Vaximm Ag | PD-L1 targeting DNA vaccine for cancer immunotherapy |
| CA3109430A1 (en) * | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| AU2021208400A1 (en) * | 2020-01-13 | 2022-08-11 | Vaximm Ag | Salmonella-based DNA vaccines in combination with an antibiotic |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094410B2 (en) | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| BR112014015706A2 (pt) * | 2011-12-22 | 2020-10-27 | Vaximm Ag | método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a |
| BR112014033046A2 (pt) * | 2012-07-05 | 2017-06-27 | Vaximm Ag | linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01 |
| PT2897620T (pt) * | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
| SG10201710472PA (en) * | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| CN105246496A (zh) * | 2013-04-25 | 2016-01-13 | 万科斯蒙股份有限公司 | 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体 |
| BR112016014405A2 (pt) * | 2013-12-18 | 2018-02-20 | Vaximm Gmbh | cepa mutante atenuada de salmonela |
| SG11201907391SA (en) * | 2017-02-17 | 2019-09-27 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| US11357842B2 (en) * | 2017-03-17 | 2022-06-14 | Vaximm Ag | PD-L1 targeting DNA vaccine for cancer immunotherapy |
-
2016
- 2016-06-16 JP JP2017565248A patent/JP6947649B2/ja active Active
- 2016-06-16 SI SI201630549T patent/SI3310379T1/sl unknown
- 2016-06-16 RU RU2018101722A patent/RU2018101722A/ru not_active Application Discontinuation
- 2016-06-16 KR KR1020257001040A patent/KR20250024816A/ko active Pending
- 2016-06-16 CN CN201680035593.2A patent/CN107995868B/zh active Active
- 2016-06-16 US US15/737,659 patent/US10905752B2/en active Active
- 2016-06-16 PL PL16736381T patent/PL3310379T3/pl unknown
- 2016-06-16 DK DK16736381.1T patent/DK3310379T3/da active
- 2016-06-16 KR KR1020187001398A patent/KR20180037948A/ko not_active Ceased
- 2016-06-16 LT LTEP16736381.1T patent/LT3310379T/lt unknown
- 2016-06-16 WO PCT/EP2016/001004 patent/WO2016202459A1/en not_active Ceased
- 2016-06-16 ES ES16736381T patent/ES2760699T3/es active Active
- 2016-06-16 EP EP16736381.1A patent/EP3310379B1/en active Active
- 2016-06-16 ES ES19205420T patent/ES2994561T3/es active Active
- 2016-06-16 HU HUE16736381A patent/HUE046631T2/hu unknown
- 2016-06-16 CA CA2989247A patent/CA2989247C/en active Active
- 2016-06-16 BR BR112017027378-0A patent/BR112017027378A2/pt not_active Application Discontinuation
- 2016-06-16 MX MX2017016183A patent/MX2017016183A/es unknown
- 2016-06-16 PL PL19205420.3T patent/PL3626262T3/pl unknown
- 2016-06-16 EP EP19205420.3A patent/EP3626262B1/en active Active
- 2016-06-16 AU AU2016278588A patent/AU2016278588B2/en active Active
-
2017
- 2017-12-04 IL IL256076A patent/IL256076A/en unknown
- 2017-12-12 ZA ZA2017/08439A patent/ZA201708439B/en unknown
-
2020
- 2020-11-30 US US17/107,203 patent/US20210077605A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517419A5 (cg-RX-API-DMAC7.html) | ||
| Kallert et al. | Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy | |
| Xie et al. | Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity | |
| Saha et al. | Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma | |
| Pol et al. | Maraba virus as a potent oncolytic vaccine vector | |
| Kuryk et al. | Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model | |
| JP2011500718A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511139A5 (cg-RX-API-DMAC7.html) | ||
| Fu et al. | Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| RU2016129044A (ru) | Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Farrera-Sal et al. | Evolving status of clinical immunotherapy with oncolytic adenovirus | |
| Ylösmäki et al. | Personalized cancer vaccine platform for clinically relevant oncolytic enveloped viruses | |
| Hu et al. | Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against TB in mice | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| US10987432B2 (en) | Therapeutic delivery and expression system, methods and uses thereof | |
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| RU2015103758A (ru) | Днк-вакцина для применения у пациентов с раком поджелудочной железы | |
| Chen et al. | Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma | |
| Fan et al. | Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| JP2007020586A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas |